| 0 | ℹ |
Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.
(linkinghub.elsevier.com)
|
The Lancet 2026-02-28 | #metabolism #diabetes #cardiovascular #obesity #kidney |